Moffitt Cancer Center, Weill Cornell Medicine, and the University of North Carolina School of Medicine received a $3.5 million, five-year grant from NCI to improve screening and preventative treatment of cervical cancer for women living with HIV in low-resource countries.
The International Cardio-Oncology Society has awarded University Hospitals Harrington Heart & Vascular Institute a Center of Excellence designation in recognition of its ongoing support of cancer patients facing heart issues. This Gold Status certification, the society’s highest designation, recognizes the institute for its commitment to cardiology services for cancer patients in whom life-saving treatments may cause cardiac problems.
The V Foundation has established a grant program aimed at increasing female representation and female-led innovation in cancer research.
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
Although widespread use of immune checkpoint inhibitors in patients with advanced lung cancer has led to meaningful improvements in survival in younger patients, older patients have not experienced similar survival benefits, new research from Yale Cancer Center shows.
Results from the SWOG S1416 clinical trial showed that adding veliparib to chemotherapy can significantly extend progression-free survival times in patients with TNBC that has a “BRCA-like” phenotype.
Data from a Yale Cancer Center-led clinical trial show improved rates of survival and reduced risk of recurrence in patients taking Tagrisso (osimertinib), a targeted therapy for non-small cell lung cancer.
Merck will stop the phase III KEYNOTE-991 trial investigating Keytruda (pembrlizumab), Merck’s anti-PD-1 therapy, in combination with Xtandi (enzalutamide) and androgen deprivation therapy for the treatment of patients with metastatic, hormone-sensitive prostate cancer.
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international phase III MOMENTUM trial led by researchers at MD Anderson Cancer Center.
A proof-of-concept, single-arm, phase II clinical trial, led by investigators from the Mass General Cancer Center, reported a long-lasting response among patients who responded to the combined treatment and reveals how a targeted therapy may cooperate with an immunotherapy for better results.
